𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Angiotensin-converting enzyme inhibition as a therapeutic principle in Bartter's syndrome

✍ Scribed by P. Jest; K. E. Pedersen; N. A. Klitgaard; N. Thomsen; K. Kjaer; E. Simonsen

Book ID
104718869
Publisher
Springer
Year
1991
Tongue
English
Weight
315 KB
Volume
41
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

The effect of captopril has been investigated in four patients with Bartter's syndrome treated for 12 weeks. Baseline biochemistry showed normal serum aldosterone (mean 347 pmol.l-1) and a mean serum renin of 217 mU-l-1, and a considerable increase in serum renin during captopril treatment. Serum aldosterone decreased gradually during the study period to about half its initial value. The patients presented with a mean serum potassium of 2.5 mmol.l-1, which rose to 3.4 mmol.l-1 on captopril. Lymphocytes showed a substantial captopril-induced increase in intracellular sodium (from 15 to 22.5 mmol.l-1 on average), but no change in the potassium content. Captopril was well-tolerated. It may be an alternative to potassium-sparing diuretics for maintaining normal serum potassium levels in patients with Bartter's syndrome.

πŸ“œ SIMILAR VOLUMES

Metabolic effects of long-term angiotens
Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition
✍ R. Reneland; P.-E. Andersson; A. Haenni; H. Lithell πŸ“‚ Article πŸ“… 1994 πŸ› Springer 🌐 English βš– 566 KB

Fifty patients with mild to moderate essential hypertension were randomized to receive either 20 mg fosinopril daily for 16 weeks or placebo for 4 weeks followed by 12 weeks of 50 mg atenolol daily. Prior to these 16 weeks there was a placebo wash-out period of 2-6 weeks. Blood pressure measurements